AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
| Revenue (TTM) | $61.37B |
| Gross Profit (TTM) | $50.13B |
| EBITDA | $19.90B |
| Operating Margin | 23.50% |
| Return on Equity | 22.00% |
| Return on Assets | 8.02% |
| Revenue/Share (TTM) | $39.59 |
| Book Value | $32.43 |
| Price-to-Book | 5.08 |
| Price-to-Sales (TTM) | 4.11 |
| EV/Revenue | 4.583 |
| EV/EBITDA | 13.82 |
| Quarterly Earnings Growth (YoY) | 2.50% |
| Quarterly Revenue Growth (YoY) | 6.40% |
| Shares Outstanding | $1.55B |
| Float | $1.54B |
| % Insiders | 0.05% |
| % Institutions | 64.84% |
Volatility is currently contracting
AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.
AstraZeneca said on Tuesday its cancer drug Imfinzi combined with Amgen's targeted immunotherapy Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial.
AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be a breakthrough treatment for COPD and reach AstraZeneca's peak annual sales forecast of more than $5 billion for the drug.
Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination with a CDK4/6 inhibitor for hormone receptor positive, HER2 negative metastatic breast cancer.
AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.
AstraZeneca said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first-line treatment for a type of lung cancer.
AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) said its drug Tezspire worked in a late-stage trial of patients with eosinophilic esophagitis, a chronic condition that inflames the gullet and makes swallowing difficult. The drug, developed with the American biotech company Amgen, hit both of its main goals and every important secondary one.
AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen , met its main and secondary goals in a late-stage trial for treating eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZN and any ticker you trade — then tracks every position and per-strategy win rate.
